MedTrace Logo

Metformin Plus Megestrol Acetate As a Fertility-sparing Treatment in Patients with Atypical Endometrial Hyperplasia

NCT04607252 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-09-26

No results posted yet for this study

Summary

To verify whether metformin could improve the effect of progestin as fertility-sparing treatment in patients with atypical endometrial hyperplasia(AEH).

Conditions

  • Atypical Endometrial Hyperplasia

Interventions

DRUG

Metformin plus Megestrol acetate

metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral

DRUG

Megestrol Acetate

megestrol acetate 160mg per day, oral

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xiaojun Chen, PHD · Obstetrics & Gynecology Hospital of Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-11
Primary Completion
2021-06-03
Completion
2021-06-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04607252 on ClinicalTrials.gov